Mid-range Ejection Fraction Does Not Permit Risk Stratification Among Patients Hospitalized for Heart Failure;La fracción de eyección intermedia no permite estratificar el riesgo de los pacientes hospitalizados por insuficiencia cardiaca

Revista Espanola de Cardiologia

Volumn 70, Issue 5, 2017, Pages 338-346

  Gómez Otero, Inés ^a   Ferrero Gregori, Andreu ^b   Varela Román, Alfonso ^a   Seijas Amigo, José ^a   Pascual Figal, Domingo A ^c   Delgado Jiménez, Juan ^d   Álvarez García, Jesús ^b   Fernández Avilés, Francisco ^e   Worner Diz, Fernando ^f   Alonso Pulpón, Luis ^g   Cinca, Juan ^b   Gónzalez Juanatey, José Ramón ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f HOSPITAL ARNAU DE VILANOVA   (Spain)

^g HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Clinical characteristics; Heart failure; Mid range ejection fraction; Prognosis

Indexed keywords

AGE; ARTICLE; ATRIAL FIBRILLATION; BLOOD PRESSURE; CAUSE OF DEATH; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREVALENCE; PROPENSITY SCORE; PROSPECTIVE STUDY; AGED; FEMALE; HEART STROKE VOLUME; HOSPITALIZATION; MIDDLE AGED; PROGNOSIS; RISK ASSESSMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPENSITY SCORE; RISK ASSESSMENT; STROKE VOLUME;

EID: 85008947586     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2016.08.019     Document Type: Article

References (23)

1. 1 Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 37 (2016), 2129–2200.
2. 2 Butler, J., Fonarow, G.C., Zile, M.R., et al. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail. 2 (2014), 97–112.
3. 3 Alonso-Pulpón, L., Borrás, X., Brugada, J., et al., Investigadores de REDINSCOR. Clinical and Preclinical Heart Failure Research Network (REDINSCOR). Instituto de Salud Carlos III Cooperative Special Topic Research Networks. Rev Esp Cardiol. 61 (2008), 76–81.
4. 4 Austin, P.C., An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 46 (2011), 399–424.
5. 5 Montañés, R., Bover, J., Oliver, A., Ballarín, J.A., Gràcia, S., Assessment of the new CKD-EPI equation to estimate the glomerular filtration rate. Nefrologia. 30 (2010), 185–194.
6. 6 Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 40 (1987), 373–383.
7. 7 Mahoney, F.I., Barthel, D.W., Functional evaluation: the Barthel Index. Md Med J. 14 (1965), 61–65.
8. 8 Martinez de la Iglesia, J., Duenas Herrero, R., Onis Vilches, M.C., Aguado Taberne, C., Albert Colomer, C., Luque Luque, R., Adaptación y validación al castellano del cuestionario de Pfeiffer (SPMSQ) para detectar la existenica de deterioro cognitivo en personas mayores de 65 años. Med Clin (Barc). 117 (2001), 129–134.
9. 9 Gray, R.J., A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 16 (1988), 1141–1154.
10. 10 Pintilie, M., An introduction to competing risks analysis. Rev Esp Cardiol. 64 (2011), 599–605.
11. 11 Fine, J.P., Gray, R.J., A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 94 (1999), 496–509.
12. 12 Maggioni, A.P., Anker, S.D., Dahlström, U., et al., Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 15 (2013), 1173–1184.
13. 13 Fonarow, G.C., Stough, W.G., Abraham, W.T., et al., OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 50 (2007), 768–777.
14. 14 Ho, J.E., Lyass, A., Lee, D.S., et al. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circ Heart Fail. 6 (2013), 279–286.
15. 15 Loop, M.S., Van Dyke, M.K., Chen, L., et al. Comparison of length of stat, 30-day mortality, and 30-day reamission rates in medicare patients with heart failure and with reduced versus preserved ejection fraction. Am J Cardiol. 118 (2016), 79–85.
16. 16 Solomon, S.D., Claggett, B., Lewis, E.F., et al., for the TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 37 (2016), 455–462.
17. 17 Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. 33 (2012), 1750–1757.
18. 18 Ather, S., Chan, W., Bozkurt, B., et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 59 (2012), 998–1005.
19. 19 Solomon, S.D., Wang, D., Finn, P., et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 110 (2004), 2180–2183.
20. 20 Henkel, D.M., Redfield, M.M., Weston, S.A., Gerber, Y., Roger, V.L., Death in heart failure: a community perspective. Circ Heart Fail. 1 (2008), 91–97.
21. 21 Hai, S.H.J.J., Chan, P.H.M., Huang, D., et al. Clinical characteristics, management, and outcomes of hospitalized heart failure in Chinese population—The Hong Kong Heart Failure Registry. J Card Fail., 2016 Disponible en: http://dx.doi.org/10.1016/j.cardfail.2016.03.007.
22. 22 Varela-Roman, A., Grigorian, L., Barge, E., Bassante, P., De la Peña, M.G., Gonzalez-Juanatey, J.R., Heart failure in patients with preserved and deteriorated left ventricular ejection fraction. Heart. 91 (2005), 489–494.
23. 23 Grigorian-Shamagian, L., Otero Raviña, F., Abu Assi, E., et al. Why and when do patients with heart failure and normal left ventricular ejection fraction die? Analysis of >600 deaths in a community long-term study. Am Heart J. 156 (2008), 1184–1190.